-
The effect of caloric restriction upon metabolism was gated by whether sugars or fats were preferentially restricted. A low-glycemic load diet (glucose restriction) yielded more favorable biochemical profiles than restricting fats.
-
Consolidation therapy with oregovomab did not significantly improve TTR overall. A set of confirmatory phase III studies has been initiated to determine whether the SFLT population derives benefit from oregovomab treatment.
-
Womens Health Initiative (WHI) investigators from Wayne State University performed an analysis using the WHI database and presented the results at the 2004 annual meeting of the American Society of Reproductive Medicine (ASRM). Two months later, the presentation on the effects of oral contraception on cardiovascular disease drew a critical response from the director of the WHI, Barbara Alving, MD, who is also the acting director of the National Heart, Lung, and Blood Institute.
-
A Crackdown on Importation of Drugs; FDA Actions.
-
-
Increased hospitalizations for abnormal bleeding were found in new users of selective serotonin reuptake inhibitor (SSRI) antidepressants, with more risk associated with SSRIs containing greater degrees of serotonin reuptake inhibition.
-
Examining data from a 20-year time period, correlations were sought between antisecretory drug therapy and cumulative incidence of dysplasia. Incidence of dysplasia was significantly lower in patients who had received proton pump inhibitor therapy vs no therapy or H2-receptor antagonists.
-
Although chronic oral antiarrhythmic prophylaxis and catheter ablation both enjoy great success for preventing recurrences of atrial fibrillation (AF), some patients are not appropriate candidates for either method, especially patients with infrequent recurrences of AF.
-
Statins lower the levels of c-reactive protein (CRP) as well as the levels of LDL cholesterol (LDL-C). Whether lowering the CRP affects the clinical outcomes of statin therapy has not previously been investigated.
-
The addition of antiplatelet therapy to reduced intensity anticoagulation in atrial fibrillation patients reduces death and embolic events without increasing bleeding.
